Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04419714Not ApplicableCompleted

TatchSleep as a Tool to Aid in Sleep Apnea Analysis

Role: lead

NCT07095413Not ApplicableNot Yet Recruiting

Assessing the Performance of Wesper Lab for Obstructive and Central Sleep Apnea

Role: lead

NCT06218186Not ApplicableUnknown

Assessing the Performance of Wesper Lab for Sleep Apnea Diagnosis in Pediatric Populations

Role: lead

All 3 trials loaded